Triethylenetetramine

Evidence Level: L5

Predicted Indications: 7

Triethylenetetramine

Pharmacist Assessment Report

Triethylenetetramine: Thyroid gland undifferentiated (anaplastic) carcinoma

One-Sentence Summary

Triethylenetetramine (trientine) is a copper chelator, listed for Wilson disease, iron metabolism disorders and several renal cell carcinoma subtypes. Any prediction scores on this page come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The TxGNN model predicts it may be effective for thyroid gland undifferentiated (anaplastic) carcinoma, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Thyroid gland undifferentiated (anaplastic) carcinoma
TxGNN Prediction Score	0.9987
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, trientine is a copper chelator. Its efficacy in Wilson disease, a disorder of copper accumulation, is established, and mechanistically it may be applicable to other conditions in which copper plays a role.

Copper is a cofactor in angiogenic and signaling pathways, such as VEGF and MEK1/2-BRAF signaling (sometimes called “cuproplasia”). Depleting copper is therefore a plausible antitumor concept. The model may also reflect similarities it learned between related diseases, such as the several renal cell carcinoma indications listed for this drug, which may partly explain why it connects the drug to other tumors; this is not biological evidence.

This reasoning is hypothetical. No trials or literature were found for anaplastic thyroid carcinoma, and the high TxGNN score is a computational prediction, not clinical evidence.

Other predicted indications (all prediction only, no trials or literature):

Rank	Predicted Indication	Score	Evidence Level	Comment
2	Hepatopulmonary syndrome	0.9977	L5	No direct mechanistic link; speculative connection through chronic liver disease
3	Early-onset familial noncirrhotic portal hypertension	0.9977	L5	Linked to the hepatic vascular network shared with Wilson disease
4	Hepatoportal sclerosis	0.9977	L5	Indirect link to copper chelation
5	Primitive portal vein thrombosis	0.9977	L5	No clear rationale; score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence
6	Idiopathic copper-associated cirrhosis	0.9977	L5	Most biologically plausible; shares hepatic copper accumulation with Wilson disease; a candidate for focused literature review
7	Hepatic porphyria	0.9971	L5	Heme synthesis is metal-dependent; no direct rationale

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02515067	WAYMADE-TRIENTINE	Not specified	Not specified
02504855	MAR-TRIENTINE	Not specified	Not specified

Both products are valid single-ingredient licences.

Safety Considerations

Contraindication signals from the knowledge graph (not label text): The knowledge graph links the drug to a broad set of conditions, including:

Cardiovascular: hypertension, long QT syndrome (including familial), torsades de pointes, myocardial infarction, coronary thrombosis, peripheral vascular disease, intermittent claudication
Liver and bilirubin: liver failure, drug-induced liver injury, hyperbilirubinaemia (including Gilbert syndrome)
Endocrine and metabolic: adrenocortical insufficiency, Addison disease, hypothyroidism (including myxedema and congenital hypothyroidism), potassium deficiency, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders
Other: hemoglobinopathy, diarrhoeal disease, skin atrophy, telangiectasis, capillary disease, hereditary hemorrhagic telangiectasia

These are database associations and should be verified against the official product monograph.

Drug Interactions: 27 interactions were identified in total. The 20 detailed records are all rated Moderate and involve mineral and trace-element products, which is consistent with chelation. They include:

Calcium salts (phosphate, acetate, carbonate, citrate, glubionate, gluconate, lactate)
Magnesium salts (oxide, carbonate, chloride, citrate)
Iron preparations (iron, ferrous fumarate, ferrous gluconate, ferrous sulfate, iron protein succinylate, tetraferric tricitrate)
Copper gluconate, selenium and manganese sulfate

Please refer to the package insert for warnings and formal contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The anaplastic thyroid carcinoma prediction has a very high model score but no clinical trials or literature, so it remains at evidence level L5. The mechanistic argument (copper depletion) is plausible but untested for this indication. Official safety information has not been obtained.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Detailed mechanism of action data
A systematic literature and trial search on copper chelation in anaplastic thyroid carcinoma
A focused review of idiopathic copper-associated cirrhosis, the most biologically plausible alternative (L4)
Preclinical or early-phase data showing antitumour activity of trientine in the predicted indication
A dosage form and indication review for the two Canadian products, whose records are incomplete
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.